Crescita Debt To Equity from 2010 to 2026

CTX Stock  CAD 0.47  0.02  4.08%   
Crescita Therapeutics Debt To Equity yearly trend continues to be very stable with very little volatility. Debt To Equity is likely to drop to 0.06. Debt To Equity is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. View All Fundamentals
 
Debt To Equity  
First Reported
2010-12-31
Previous Quarter
0.0606
Current Value
0.0576
Quarterly Volatility
0.11925907
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check Crescita Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Crescita Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Interest Expense of 55.6 K or Selling General Administrative of 10.5 M, as well as many indicators such as Price To Sales Ratio of 0.62, Dividend Yield of 0.0 or PTB Ratio of 0.67. Crescita financial statements analysis is a perfect complement when working with Crescita Therapeutics Valuation or Volatility modules.
  
This module can also supplement various Crescita Therapeutics Technical models . Check out the analysis of Crescita Therapeutics Correlation against competitors.
Evaluating Crescita Therapeutics's Debt To Equity across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Crescita Therapeutics's fundamental strength.

Latest Crescita Therapeutics' Debt To Equity Growth Pattern

Below is the plot of the Debt To Equity of Crescita Therapeutics over the last few years. It is a measure of a company's financial leverage calculated by dividing its total liabilities by stockholders' equity, indicating the proportion of equity and debt the company is using to finance its assets. Crescita Therapeutics' Debt To Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Crescita Therapeutics' overall financial position and show how it may be relating to other accounts over time.
ViewLast Reported 0.08 %10 Years Trend
Slightly volatile
   Debt To Equity   
       Timeline  

Crescita Debt To Equity Regression Statistics

Arithmetic Mean0.19
Geometric Mean0.15
Coefficient Of Variation61.85
Mean Deviation0.11
Median0.23
Standard Deviation0.12
Sample Variance0.01
Range0.2764
R-Value(0.89)
Mean Square Error0
R-Squared0.79
Slope(0.02)
Total Sum of Squares0.23

Crescita Debt To Equity History

2026 0.0576
2025 0.0606
2024 0.0527
2023 0.0666
2022 0.0765
2021 0.14
2020 0.0582

About Crescita Therapeutics Financial Statements

Crescita Therapeutics investors utilize fundamental indicators, such as Debt To Equity, to predict how Crescita Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Debt To Equity 0.06  0.06 

Other Information on Investing in Crescita Stock

Crescita Therapeutics financial ratios help investors to determine whether Crescita Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Crescita with respect to the benefits of owning Crescita Therapeutics security.